Sanofi: positive results for Toujeo in diabetes

(CercleFinance.com) - Sanofi has announced positive results of a phase III trial for Toujeo in the treatment of Type 1 diabetes in children and adolescents, at the Congress of the International Society for Pediatric and Adolescent Diabetes in Boston.


Patients aged 6 to 17 years old treated with Toujeo (insulin glargine 300 units/ml) achieved a comparable reduction in their average blood sugar level and presented the same risks of hypoglycaemia episodes as those treated with glargine 100 units/ml.

On this basis, the CHMP of the European Medicines Agency has recommended the extension of its current indication for Toujeo to children and adolescents with Type 1 diabetes. The European Commission will make its final decision in the coming months.


Copyright (c) 2019 CercleFinance.com. All rights reserved.